Lantheus (LNTH) Revenue & Revenue Breakdown
Lantheus Revenue Highlights
Latest Revenue (Y)
$1.30B
Latest Revenue (Q)
$394.09M
Main Segment (Y)
Product
Main Geography (Y)
US Segment
Lantheus Revenue by Period
Lantheus Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $1.30B | 38.65% |
| 2022-12-31 | $935.06M | 119.91% |
| 2021-12-31 | $425.21M | 25.28% |
| 2020-12-31 | $339.41M | -2.28% |
| 2019-12-31 | $347.34M | 1.15% |
| 2018-12-31 | $343.37M | 3.62% |
| 2017-12-31 | $331.38M | 9.78% |
| 2016-12-31 | $301.85M | 2.86% |
| 2015-12-31 | $293.46M | -2.70% |
| 2014-12-31 | $301.60M | 6.32% |
| 2013-12-31 | $283.67M | -1.54% |
| 2012-12-31 | $288.11M | -19.14% |
| 2011-12-31 | $356.29M | - |
Lantheus generated $1.30B in revenue during NA 2023, up 38.65% compared to the previous quarter, and up 377.56% compared to the same period a year ago.
Lantheus Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $394.09M | 6.52% |
| 2024-03-31 | $369.98M | 4.51% |
| 2023-12-31 | $354.00M | 10.64% |
| 2023-09-30 | $319.95M | -0.55% |
| 2023-06-30 | $321.70M | 6.95% |
| 2023-03-31 | $300.78M | 14.29% |
| 2022-12-31 | $263.17M | 9.98% |
| 2022-09-30 | $239.29M | 6.96% |
| 2022-06-30 | $223.72M | 7.11% |
| 2022-03-31 | $208.88M | 61.22% |
| 2021-12-31 | $129.56M | 26.93% |
| 2021-09-30 | $102.07M | 1.00% |
| 2021-06-30 | $101.06M | 9.25% |
| 2021-03-31 | $92.51M | -1.75% |
| 2020-12-31 | $94.15M | 6.33% |
| 2020-09-30 | $88.54M | 34.14% |
| 2020-06-30 | $66.01M | -27.22% |
| 2020-03-31 | $90.70M | 1.52% |
| 2019-12-31 | $89.35M | 4.16% |
| 2019-09-30 | $85.78M | 0.08% |
| 2019-06-30 | $85.70M | -0.93% |
| 2019-03-31 | $86.51M | 0.28% |
| 2018-12-31 | $86.27M | -2.96% |
| 2018-09-30 | $88.90M | 3.89% |
| 2018-06-30 | $85.57M | 3.56% |
| 2018-03-31 | $82.63M | 1.71% |
| 2017-12-31 | $81.24M | 1.63% |
| 2017-09-30 | $79.94M | -10.01% |
| 2017-06-30 | $88.84M | 9.19% |
| 2017-03-31 | $81.36M | 9.43% |
| 2016-12-31 | $74.35M | 1.76% |
| 2016-09-30 | $73.06M | -6.29% |
| 2016-06-30 | $77.97M | 1.95% |
| 2016-03-31 | $76.47M | 7.41% |
| 2015-12-31 | $71.20M | -3.94% |
| 2015-09-30 | $74.12M | 1.10% |
| 2015-06-30 | $73.31M | -2.02% |
| 2015-03-31 | $74.82M | -2.79% |
| 2014-12-31 | $76.97M | 1.70% |
| 2014-09-30 | $75.68M | 0.09% |
| 2014-06-30 | $75.61M | 3.10% |
| 2014-03-31 | $73.34M | 2.33% |
| 2013-12-31 | $71.67M | 1.82% |
| 2013-09-30 | $70.39M | -0.31% |
| 2013-06-30 | $70.60M | -0.59% |
| 2013-03-31 | $71.02M | - |
Lantheus generated $394.09M in revenue during Q2 2024, up 6.52% compared to the previous quarter, and up 131.02% compared to the same period a year ago.
Lantheus Revenue Breakdown
Lantheus Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Techne Lite | $87.37M | $88.86M | $91.29M | - | - |
| License and Royalty Revenues | $33.36M | $48.02M | $24.85M | - | - |
| Total Precision Diagnostics | $390.12M | $356.68M | $351.02M | - | - |
| Product | $1.26B | - | - | - | - |
| Radiopharmaceutical Oncology | $854.43M | $531.51M | $48.89M | - | - |
| Strategic Partnerships And Other | $51.88M | $46.87M | $25.30M | - | - |
| Other Precision Diagnostics | $22.98M | $22.82M | $26.97M | - | - |
| Other Radiopharmaceutical Oncology | $3.13M | $4.10M | $5.47M | - | - |
| PYLARIFY | $851.30M | $527.40M | $43.41M | - | - |
| DEFINITY | $279.77M | $244.99M | $232.76M | - | - |
| Product Revenue, Net | - | $887.04M | $400.36M | - | - |
| US Segment | - | - | - | $294.80M | $303.99M |
| International Segment | - | - | - | $44.61M | $43.35M |
Lantheus's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (32.91%), Radiopharmaceutical Oncology (22.27%), PYLARIFY (22.18%), Total Precision Diagnostics (10.17%), DEFINITY (7.29%), Techne Lite (2.28%), Strategic Partnerships And Other (1.35%), License and Royalty Revenues (0.87%), Other Precision Diagnostics (0.60%), and Other Radiopharmaceutical Oncology (0.08%).
Quarterly Revenue by Product
| Product/Service | Jun 24 | Mar 24 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Precision Diagnostics | $112.11M | $104.21M | $96.35M | $97.58M | $95.62M | $94.37M | $89.01M | $87.11M | $86.20M | $87.04M | $87.88M | $90.36M | $85.75M | - | - | - | - | - | - | - |
| Techne Lite | $28.19M | $21.71M | $23.27M | $21.59M | $20.99M | $24.73M | $22.09M | $19.44M | $22.61M | $22.04M | $22.68M | $23.77M | $22.80M | - | - | - | - | - | - | - |
| Strategic Partnerships And Other | $8.72M | $6.51M | $7.32M | $12.78M | $8.98M | $7.24M | $5.60M | $5.45M | $28.58M | $6.84M | $5.30M | $7.90M | $5.25M | - | - | - | - | - | - | - |
| Radiopharmaceutical Oncology | $273.25M | $259.25M | $216.28M | $211.34M | $196.19M | $161.56M | $144.68M | $131.16M | $94.10M | $35.68M | $8.89M | $2.81M | $1.50M | - | - | - | - | - | - | - |
| Product | $392.76M | $369.31M | $319.51M | $314.08M | $292.26M | $233.37M | $217.78M | $180.01M | $96.68M | $93.56M | $87.32M | - | - | - | - | - | - | - | - | - |
| PYLARIFY | $273.25M | $258.87M | $215.43M | $210.52M | $195.47M | $160.64M | $143.75M | $130.23M | $92.78M | - | - | - | - | - | - | - | - | - | - | - |
| Other Radiopharmaceutical Oncology | - | $384.00K | $848.00K | $818.00K | $717.00K | $919.00K | $928.00K | $928.00K | $1.33M | - | - | - | - | - | - | - | - | - | - | - |
| Other Precision Diagnostics | $5.83M | $5.93M | $5.74M | $5.45M | $5.81M | $6.02M | $6.17M | $5.36M | $5.26M | $5.68M | $7.56M | $6.74M | $6.98M | - | - | - | - | - | - | - |
| License and Royalty Revenues | $1.33M | $662.00K | $438.00K | $7.62M | $8.53M | $7.29M | $5.93M | $5.94M | $28.87M | $6.76M | $5.39M | $7.50M | $5.19M | - | - | - | - | - | - | - |
| DEFINITY | $78.10M | $76.56M | $67.34M | $70.53M | $68.82M | $63.62M | $60.74M | $62.31M | $58.33M | $59.31M | $57.64M | $59.84M | $55.97M | - | - | - | - | - | - | - |
| International Segment | - | - | - | - | - | - | - | - | - | - | - | - | - | $12.97M | $11.07M | $8.61M | $11.96M | $10.63M | $11.13M | $10.52M |
| US Segment | - | - | - | - | - | - | - | - | - | - | - | - | - | $81.18M | $77.47M | $57.40M | $78.75M | $78.72M | $74.65M | $75.19M |
Lantheus's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: Product (33.47%), Radiopharmaceutical Oncology (23.28%), PYLARIFY (23.28%), Total Precision Diagnostics (9.55%), DEFINITY (6.66%), Techne Lite (2.40%), Strategic Partnerships And Other (0.74%), Other Precision Diagnostics (0.50%), and License and Royalty Revenues (0.11%).
Lantheus Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 20 | Dec 19 | Dec 18 |
|---|---|---|---|
| US Segment | $294.80M | $72.53M | - |
| Worldwide | - | $347.34M | - |
| All Other | - | - | $54.79M |
| UNITED STATES | - | - | $288.58M |
Lantheus's latest annual revenue breakdown by geography, as of Dec 20: US Segment (100.00%).
Quarterly Revenue by Country
| Country | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | Jun 18 | Mar 18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| US Segment | $81.18M | $77.47M | $57.40M | $19.36M | $78.72M | $74.65M | $75.19M | $75.43M | $72.75M | $70.25M | $74.09M | $71.49M |
Lantheus's latest quarterly revenue breakdown by geography, as of Dec 20: US Segment (100.00%).
Lantheus Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| RDY | Dr. Reddy's Laboratories | $279.16B | - |
| CTLT | Catalent | $4.38B | $1.07B |
| NBIX | Neurocrine Biosciences | $1.89B | $590.20M |
| ALKS | Alkermes | $1.66B | $399.13M |
| LNTH | Lantheus | $1.30B | $394.09M |
| PCRX | Pacira BioSciences | $674.98M | $178.02M |
| AMPH | Amphastar Pharmaceuticals | $593.24M | $182.39M |
| COLL | Collegium Pharmaceutical | $566.77M | $144.92M |
| ANIP | ANI Pharmaceuticals | $486.82M | $138.04M |
| IRWD | Ironwood Pharmaceuticals | $442.74M | $94.40M |
| DVAX | Dynavax | $232.28M | $73.80M |
| DCPH | Deciphera Pharmaceuticals | $163.36M | $45.00M |
| DERM | Journey Medical | $79.18M | $14.86M |
| AQST | Aquestive Therapeutics | $50.58M | $20.10M |
| AVDL | Avadel Pharmaceuticals | $27.96M | $41.50M |
LNTH Revenue FAQ
What is Lantheus’s yearly revenue?
Lantheus's yearly revenue for 2023 was $1.3B, representing an increase of 38.65% compared to 2022. The company's yearly revenue for 2022 was $935.06M, representing an increase of 119.91% compared to 2021. LNTH's yearly revenue for 2021 was $425.21M, representing an increase of 25.28% compared to 2020.
What is Lantheus’s quarterly revenue?
Lantheus's quarterly revenue for Q2 2024 was $394.09M, a 6.52% increase from the previous quarter (Q1 2024), and a 22.50% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $369.98M, a 4.51% increase from the previous quarter (Q4 2023), and a 23.00% increase year-over-year (Q1 2023). LNTH's quarterly revenue for Q4 2023 was $354M, a 10.64% increase from the previous quarter (Q3 2023), and a 34.52% increase year-over-year (Q4 2022).
What is Lantheus’s revenue growth rate?
Lantheus's revenue growth rate for the last 3 years (2021-2023) was 204.89%, and for the last 5 years (2019-2023) was 273.25%.
What are Lantheus’s revenue streams?
Lantheus's revenue streams in c 23 are Techne Lite, License and Royalty Revenues, Total Precision Diagnostics, Product, Radiopharmaceutical Oncology, Strategic Partnerships And Other, Other Precision Diagnostics, Other Radiopharmaceutical Oncology, PYLARIFY, and DEFINITY. Techne Lite generated $87.37M in revenue, accounting 2.28% of the company's total revenue, down -1.68% year-over-year. License and Royalty Revenues generated $33.36M in revenue, accounting 0.87% of the company's total revenue, down -30.53% year-over-year. Total Precision Diagnostics generated $390.12M in revenue, accounting 10.17% of the company's total revenue, up 9.37% year-over-year. Product generated $1.26B in revenue, accounting 32.91% of the company's total revenue Radiopharmaceutical Oncology generated $854.43M in revenue, accounting 22.27% of the company's total revenue, up 60.76% year-over-year. Strategic Partnerships And Other generated $51.88M in revenue, accounting 1.35% of the company's total revenue, up 10.68% year-over-year. Other Precision Diagnostics generated $22.98M in revenue, accounting 0.60% of the company's total revenue, up 0.68% year-over-year. Other Radiopharmaceutical Oncology generated $3.13M in revenue, accounting 0.08% of the company's total revenue, down -23.70% year-over-year. PYLARIFY generated $851.3M in revenue, accounting 22.18% of the company's total revenue, up 61.41% year-over-year. DEFINITY generated $279.77M in revenue, accounting 7.29% of the company's total revenue, up 14.19% year-over-year.
What is Lantheus’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Lantheus was Product. This segment made a revenue of $1.26B, representing 32.91% of the company's total revenue.